Showing 5 posts of 5 posts found.

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

September 7, 2023
Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …


Valneva COVID-19 vaccine deal pulled by UK government

September 13, 2021
Research and Development, Sales and Marketing Boris Johnson, Scotland, UK government, Vaccine, Valneva, booster, covid19

Boris Johnson and the UK government have terminated its deal with specialist vaccine company Valneva after it was alleged the …

Valneva’s inactivated COVID-19 vaccine candidate advances to Phase III trial

April 6, 2021
Manufacturing and Production COVID-19, COVID-19 vaccine, Valneva, Valneva vaccine, inactivated vaccine

Specialty vaccine company Valneva’s inactivated COVID-19 jab has shown positive results in a Phase I/II trial, with a seroconversion rate …


Valneva begins production of its COVID-19 vaccine

January 28, 2021
COVID-19, Valneva

Valneva, a specialty vaccine company focused on the prevention of infectious diseases with significant unmet medical needs, has commenced production …


FDA fast tracks Valneva’s Lyme disease vaccine

August 7, 2017
Research and Development, Sales and Marketing Valneva, biotech, life sciences, lyme disease, medicines, pharma, pharmaceutcial

French firm Valneva has announced that its Lyme disease vaccine, known at this stage only by VLA15, has been fast-tracked …

Latest content